Brandon Folkes
Stock Analyst at Rodman & Renshaw
(0.49)
# 2,966
Out of 4,829 analysts
47
Total ratings
26.67%
Success rate
-24.59%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RMTI Rockwell Medical | Initiates: Buy | $5 | $1.04 | +380.77% | 1 | Nov 14, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $2.48 | +383.87% | 1 | Nov 14, 2024 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Buy | $9 | $3.76 | +139.36% | 1 | Nov 14, 2024 | |
| OMER Omeros | Initiates: Buy | $9 | $3.80 | +137.15% | 2 | Nov 14, 2024 | |
| ADIL Adial Pharmaceuticals | Initiates: Buy | $8 | $0.61 | +1,209.33% | 1 | Nov 14, 2024 | |
| EBS Emergent BioSolutions | Reiterates: Buy | $16 | $5.84 | +173.97% | 6 | Sep 13, 2024 | |
| CRMD CorMedix | Initiates: Buy | $13 | $11.86 | +9.61% | 1 | Aug 26, 2024 | |
| MIST Milestone Pharmaceuticals | Initiates: Buy | $9 | $1.20 | +650.00% | 1 | Aug 22, 2024 | |
| MNKD MannKind | Initiates: Buy | $8 | $4.81 | +66.32% | 1 | Jun 13, 2024 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $7 | $6.70 | +4.48% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $2.05 | +241.46% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.61 | +1,531.32% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $4.10 | +10,997.56% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $34.37 | +71.66% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $103.58 | +73.78% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $0.52 | +4,122.65% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $6.83 | +31.77% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $31.27 | +2.33% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $2.00 | +1,099,900.00% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $22 | $29.56 | -25.58% | 5 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $720 | $2.85 | +25,163.16% | 1 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $78 → $40 | $62.30 | -35.79% | 3 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 → $315 | $9.42 | +3,243.95% | 3 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $20.56 | +143.19% | 1 | Jul 12, 2018 |
Rockwell Medical
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.04
Upside: +380.77%
Achieve Life Sciences
Nov 14, 2024
Initiates: Buy
Price Target: $12
Current: $2.48
Upside: +383.87%
Eupraxia Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $3.76
Upside: +139.36%
Omeros
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $3.80
Upside: +137.15%
Adial Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.61
Upside: +1,209.33%
Emergent BioSolutions
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $5.84
Upside: +173.97%
CorMedix
Aug 26, 2024
Initiates: Buy
Price Target: $13
Current: $11.86
Upside: +9.61%
Milestone Pharmaceuticals
Aug 22, 2024
Initiates: Buy
Price Target: $9
Current: $1.20
Upside: +650.00%
MannKind
Jun 13, 2024
Initiates: Buy
Price Target: $8
Current: $4.81
Upside: +66.32%
Trevi Therapeutics
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $6.70
Upside: +4.48%
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $2.05
Upside: +241.46%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $0.61
Upside: +1,531.32%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $4.10
Upside: +10,997.56%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $34.37
Upside: +71.66%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $103.58
Upside: +73.78%
Dec 5, 2022
Maintains: Overweight
Price Target: $30 → $22
Current: $0.52
Upside: +4,122.65%
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $6.83
Upside: +31.77%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $31.27
Upside: +2.33%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $2.00
Upside: +1,099,900.00%
Aug 6, 2021
Downgrades: Neutral
Price Target: $30 → $22
Current: $29.56
Upside: -25.58%
Jul 30, 2021
Initiates: Overweight
Price Target: $720
Current: $2.85
Upside: +25,163.16%
May 7, 2020
Downgrades: Neutral
Price Target: $78 → $40
Current: $62.30
Upside: -35.79%
Mar 5, 2020
Reiterates: Overweight
Price Target: $405 → $315
Current: $9.42
Upside: +3,243.95%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $20.56
Upside: +143.19%